Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients

Skeletal muscle depletion is common in patients with advanced cancer and may be associated with a poor outcome. To investigate whether the changes in skeletal muscle in metastatic renal cell carcinoma (mRCC) patients receiving targeted therapy are associated with clinical outcome, we undertook an ob...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Weijie, Wu, Junlong, Liu, Xiaohang, Zhang, Hailiang, Shi, Guohai, Zhu, Yao, Ye, Dingwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548774/
https://www.ncbi.nlm.nih.gov/pubmed/28790354
http://dx.doi.org/10.1038/s41598-017-07955-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548774/
https://www.ncbi.nlm.nih.gov/pubmed/28790354
http://dx.doi.org/10.1038/s41598-017-07955-6

Ejemplares similares